{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T16:07:03Z","timestamp":1771258023888,"version":"3.50.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL160892"],"award-info":[{"award-number":["R01HL160892"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Heart Fail Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11897-025-00696-y","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T04:34:13Z","timestamp":1739421253000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Biomarkers in Subclinical Transthyretin Cardiac Amyloidosis"],"prefix":"10.1007","volume":"22","author":[{"given":"Jaskeerat S.","family":"Gulati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rose","family":"Pedretti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Hendren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Kozlitina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorena","family":"Saelices","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori R.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin L.","family":"Grodin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"issue":"1","key":"696_CR1","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","volume":"142","author":"MM Kittleson","year":"2020","unstructured":"Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, et al. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the american heart association. Circulation. 2020;142(1):e7\u201322. https:\/\/doi.org\/10.1161\/CIR.0000000000000792.","journal-title":"Circulation"},{"issue":"16","key":"696_CR2","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","volume":"42","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working group on myocardial and pericardial diseases. Eur Heart J. 2021;42(16):1554\u201368. https:\/\/doi.org\/10.1093\/eurheartj\/ehab072.","journal-title":"Eur Heart J"},{"issue":"10038","key":"696_CR3","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","volume":"387","author":"AD Wechalekar","year":"2016","unstructured":"Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387(10038):2641\u201354. https:\/\/doi.org\/10.1016\/S0140-6736(15)01274-X.","journal-title":"Lancet"},{"issue":"5","key":"696_CR4","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1007\/s10741-021-10180-z","volume":"27","author":"P Chandrashekar","year":"2022","unstructured":"Chandrashekar P, Desai AK, Trachtenberg BH. Targeted treatments of AL and ATTR amyloidosis. Heart Fail Rev. 2022;27(5):1587\u2013603. https:\/\/doi.org\/10.1007\/s10741-021-10180-z.","journal-title":"Heart Fail Rev"},{"issue":"11","key":"696_CR5","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007\u201316. https:\/\/doi.org\/10.1056\/NEJMoa1805689.","journal-title":"N Engl J Med"},{"issue":"1","key":"696_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1080\/13506129.2017.1301419","volume":"24","author":"D Keohane","year":"2017","unstructured":"Keohane D, Schwartz J, Gundapaneni B, Stewart M, Amass L. Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid. 2017;24(1):30\u20136. https:\/\/doi.org\/10.1080\/13506129.2017.1301419.","journal-title":"Amyloid"},{"key":"696_CR7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409134","author":"M Fontana","year":"2024","unstructured":"Fontana M, Berk JL, Gillmore JD, Witteles RM, Grogan M, Drachman B, et al. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. N Engl J Med. 2024. https:\/\/doi.org\/10.1056\/NEJMoa2409134.","journal-title":"N Engl J Med"},{"issue":"1","key":"696_CR8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","volume":"140","author":"T Lane","year":"2019","unstructured":"Lane T, Fontana M, Martinez-Naharro A, Quarta CC, Whelan CJ, Petrie A, et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation. 2019;140(1):16\u201326. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.038169.","journal-title":"Circulation"},{"issue":"1","key":"696_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/13506129.2018.1556156","volume":"26","author":"I Conceicao","year":"2019","unstructured":"Conceicao I, Damy T, Romero M, Galan L, Attarian S, Luigetti M, et al. Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations. Amyloid. 2019;26(1):3\u20139. https:\/\/doi.org\/10.1080\/13506129.2018.1556156.","journal-title":"Amyloid"},{"issue":"3","key":"696_CR10","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3109\/13506120308998998","volume":"10","author":"LH Connors","year":"2003","unstructured":"Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid. 2003;10(3):160\u201384. https:\/\/doi.org\/10.3109\/13506120308998998.","journal-title":"Amyloid"},{"issue":"2","key":"696_CR11","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","volume":"68","author":"MS Maurer","year":"2016","unstructured":"Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B, et al. Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016;68(2):161\u201372. https:\/\/doi.org\/10.1016\/j.jacc.2016.03.596.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"696_CR12","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.ahj.2009.08.006","volume":"158","author":"LH Connors","year":"2009","unstructured":"Connors LH, Prokaeva T, Lim A, Theberge R, Falk RH, Doros G, et al. Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. Am Heart J. 2009;158(4):607\u201314. https:\/\/doi.org\/10.1016\/j.ahj.2009.08.006.","journal-title":"Am Heart J"},{"issue":"3","key":"696_CR13","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.cardfail.2021.09.015","volume":"28","author":"J Kozlitina","year":"2022","unstructured":"Kozlitina J, Garg S, Drazner MH, Matulevicius SA, Ayers C, Overton J, et al. Clinical implications of the amyloidogenic V122I transthyretin variant in the general population. J Card Fail. 2022;28(3):403\u201314. https:\/\/doi.org\/10.1016\/j.cardfail.2021.09.015.","journal-title":"J Card Fail"},{"issue":"14","key":"696_CR14","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1001\/jama.2022.2896","volume":"327","author":"V Parcha","year":"2022","unstructured":"Parcha V, Malla G, Irvin MR, Armstrong ND, Judd SE, Lange LA, et al. Association of transthyretin Val122Ile variant with incident heart failure among black individuals. JAMA. 2022;327(14):1368\u201378. https:\/\/doi.org\/10.1001\/jama.2022.2896.","journal-title":"JAMA"},{"issue":"22","key":"696_CR15","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2019.17935","volume":"322","author":"SM Damrauer","year":"2019","unstructured":"Damrauer SM, Chaudhary K, Cho JH, Liang LW, Argulian E, Chan L, et al. Association of the V122I hereditary transthyretin amyloidosis genetic variant with heart failure among individuals of african or hispanic\/latino ancestry. JAMA. 2019;322(22):2191\u2013202. https:\/\/doi.org\/10.1001\/jama.2019.17935.","journal-title":"JAMA"},{"issue":"2","key":"696_CR16","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1080\/13506129.2024.2322479","volume":"31","author":"NS Hendren","year":"2024","unstructured":"Hendren NS, De Lemos JA, Berry JD, Kozlitina J, Saelices L, Ji AX, et al. Circulating transthyretin and retinol binding protein 4 levels among middle-age V122I TTR carriers in the general population. Amyloid. 2024;31(2):124\u201331. https:\/\/doi.org\/10.1080\/13506129.2024.2322479.","journal-title":"Amyloid"},{"issue":"8","key":"696_CR17","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1001\/jamacardio.2023.1525","volume":"8","author":"S Selvaraj","year":"2023","unstructured":"Selvaraj S, Claggett BL, Quarta CC, Yu B, Inciardi RM, Buxbaum JN, et al. Age dependency of cardiovascular outcomes with the amyloidogenic pV142I transthyretin variant among black individuals in the US. JAMA Cardiol. 2023;8(8):784\u20138. https:\/\/doi.org\/10.1001\/jamacardio.2023.1525.","journal-title":"JAMA Cardiol"},{"issue":"21","key":"696_CR18","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1001\/jama.2024.4467","volume":"331","author":"S Selvaraj","year":"2024","unstructured":"Selvaraj S, Claggett B, Shah SH, Mentz RJ, Khouri MG, Manichaikul AW, et al. Cardiovascular burden of the V142I transthyretin variant. JAMA. 2024;331(21):1824\u201333. https:\/\/doi.org\/10.1001\/jama.2024.4467.","journal-title":"JAMA"},{"issue":"1","key":"696_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaccao.2023.12.006","volume":"6","author":"L De Michieli","year":"2024","unstructured":"De Michieli L, Cipriani A, Iliceto S, Dispenzieri A, Jaffe AS. Cardiac troponin in patients with light chain and transthyretin cardiac amyloidosis: JACC: CardioOncology State-of-the-art review. JACC CardioOncol. 2024;6(1):1\u201315. https:\/\/doi.org\/10.1016\/j.jaccao.2023.12.006.","journal-title":"JACC CardioOncol"},{"issue":"7","key":"696_CR20","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/s0002-9149(01)01877-x","volume":"88","author":"WL Miller","year":"2001","unstructured":"Miller WL, Wright RS, McGregor CG, Dispenzieri A, McConnell JP, Burritt MF, et al. Troponin levels in patients with amyloid cardiomyopathy undergoing cardiac transplantation. Am J Cardiol. 2001;88(7):813\u20135. https:\/\/doi.org\/10.1016\/s0002-9149(01)01877-x.","journal-title":"Am J Cardiol"},{"issue":"4","key":"696_CR21","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3109\/13506120903421538","volume":"16","author":"S Lehrke","year":"2009","unstructured":"Lehrke S, Steen H, Kristen AV, Merten C, Lossnitzer D, Dengler TJ, et al. Serum levels of NT-proBNP as surrogate for cardiac amyloid burden: new evidence from gadolinium-enhanced cardiac magnetic resonance imaging in patients with amyloidosis. Amyloid. 2009;16(4):187\u201395. https:\/\/doi.org\/10.3109\/13506120903421538.","journal-title":"Amyloid"},{"issue":"30","key":"696_CR22","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","volume":"39","author":"JD Gillmore","year":"2018","unstructured":"Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018;39(30):2799\u2013806. https:\/\/doi.org\/10.1093\/eurheartj\/ehx589.","journal-title":"Eur Heart J"},{"issue":"10","key":"696_CR23","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","volume":"68","author":"M Grogan","year":"2016","unstructured":"Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016;68(10):1014\u201320. https:\/\/doi.org\/10.1016\/j.jacc.2016.06.033.","journal-title":"J Am Coll Cardiol"},{"key":"696_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3455","author":"GB Bonfioli","year":"2024","unstructured":"Bonfioli GB, Tomasoni D, Vergaro G, Castiglione V, Adamo M, Fabiani I, et al. The Mayo ATTR-CM score versus other diagnostic scores and cardiac biomarkers in patients with suspected cardiac amyloidosis. Eur J Heart Fail. 2024. https:\/\/doi.org\/10.1002\/ejhf.3455.","journal-title":"Eur J Heart Fail"},{"key":"696_CR25","doi-asserted-by":"publisher","first-page":"132469","DOI":"10.1016\/j.ijcard.2024.132469","volume":"415","author":"N Noory","year":"2024","unstructured":"Noory N, Westin O, Fosbol E, Maurer MS, Gustafsson F. Value of troponin and NT-proBNP to screen for cardiac amyloidosis after carpal tunnel syndrome surgery. Int J Cardiol. 2024;415:132469. https:\/\/doi.org\/10.1016\/j.ijcard.2024.132469.","journal-title":"Int J Cardiol"},{"issue":"2","key":"696_CR26","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jchf.2021.09.006","volume":"10","author":"AC Coniglio","year":"2022","unstructured":"Coniglio AC, Segar MW, Loungani RS, Savla JJ, Grodin JL, Fox ER, et al. Transthyretin V142I genetic variant and cardiac remodeling, injury, and heart failure risk in black adults. JACC Heart Fail. 2022;10(2):129\u201338. https:\/\/doi.org\/10.1016\/j.jchf.2021.09.006.","journal-title":"JACC Heart Fail"},{"issue":"6","key":"696_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamacardio.2020.6623","volume":"6","author":"A Sinha","year":"2020","unstructured":"Sinha A, Zheng Y, Nannini D, Qu Y, Hou L, Shah SJ, et al. Association of the V122I transthyretin amyloidosis genetic variant with cardiac structure and function in middle-aged black adults: coronary artery risk development in young adults (CARDIA) study. JAMA Cardiol. 2020;6(6):1\u20135. https:\/\/doi.org\/10.1001\/jamacardio.2020.6623.","journal-title":"JAMA Cardiol"},{"issue":"5","key":"696_CR28","doi-asserted-by":"publisher","first-page":"e003356","DOI":"10.1161\/CIRCGEN.121.003356","volume":"14","author":"P Chandrashekar","year":"2021","unstructured":"Chandrashekar P, Alhuneafat L, Mannello M, Al-Rashdan L, Kim MM, Dungu J, et al. Prevalence and outcomes of p.Val142Ile TTR amyloidosis cardiomyopathy: a systematic review. Circ Genom Precis Med. 2021;14(5):e003356. https:\/\/doi.org\/10.1161\/CIRCGEN.121.003356.","journal-title":"Circ Genom Precis Med"},{"issue":"15","key":"696_CR29","doi-asserted-by":"publisher","first-page":"e028973","DOI":"10.1161\/JAHA.122.028973","volume":"12","author":"A Madhani","year":"2023","unstructured":"Madhani A, Sabogal N, Massillon D, Paul LD, Rodriguez C, Fine D, et al. Clinical penetrance of the transthyretin V122I variant in older black patients with heart failure: The SCAN-MP (Screening for cardiac amyloidosis with nuclear imaging in minority populations) study. J Am Heart Assoc. 2023;12(15):e028973. https:\/\/doi.org\/10.1161\/JAHA.122.028973.","journal-title":"J Am Heart Assoc"},{"issue":"18","key":"696_CR30","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1056\/NEJMc1503222","volume":"372","author":"CC Quarta","year":"2015","unstructured":"Quarta CC, Falk RH, Solomon SD. V122I transthyretin variant in elderly black Americans. N Engl J Med. 2015;372(18):1769. https:\/\/doi.org\/10.1056\/NEJMc1503222.","journal-title":"N Engl J Med"},{"key":"696_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/(sici)1097-0134(1998)33:2+<3::aid-prot2>3.3.co;2-8","volume":"Suppl 2","author":"AA Rostom","year":"1998","unstructured":"Rostom AA, Sunde M, Richardson SJ, Schreiber G, Jarvis S, Bateman R, et al. Dissection of multi-protein complexes using mass spectrometry: subunit interactions in transthyretin and retinol-binding protein complexes. Proteins. 1998;Suppl 2:3\u201311. https:\/\/doi.org\/10.1002\/(sici)1097-0134(1998)33:2+%3c3::aid-prot2%3e3.3.co;2-8.","journal-title":"Proteins"},{"issue":"3","key":"696_CR32","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s11897-020-00457-z","volume":"17","author":"NS Hendren","year":"2020","unstructured":"Hendren NS, Roth LR, Grodin JL. Disease-specific biomarkers in transthyretin cardiac amyloidosis. Curr Heart Fail Rep. 2020;17(3):77\u201383. https:\/\/doi.org\/10.1007\/s11897-020-00457-z.","journal-title":"Curr Heart Fail Rep"},{"issue":"26","key":"696_CR33","doi-asserted-by":"publisher","first-page":"15051","DOI":"10.1073\/pnas.93.26.15051","volume":"93","author":"GJ Miroy","year":"1996","unstructured":"Miroy GJ, Lai Z, Lashuel HA, Peterson SA, Strang C, Kelly JW. Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc Natl Acad Sci U S A. 1996;93(26):15051\u20136. https:\/\/doi.org\/10.1073\/pnas.93.26.15051.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"696_CR34","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.3390\/biomedicines10081906","volume":"10","author":"C Sanguinetti","year":"2022","unstructured":"Sanguinetti C, Minniti M, Susini V, Caponi L, Panichella G, Castiglione V, et al. The journey of human transthyretin: synthesis, structure stability, and catabolism. Biomedicines. 2022;10(8):1906. https:\/\/doi.org\/10.3390\/biomedicines10081906.","journal-title":"Biomedicines"},{"issue":"2","key":"696_CR35","doi-asserted-by":"publisher","first-page":"e004000","DOI":"10.1161\/CIRCHEARTFAILURE.117.004000","volume":"11","author":"JLS Hanson","year":"2018","unstructured":"Hanson JLS, Arvanitis M, Koch CM, Berk JL, Ruberg FL, Prokaeva T, et al. Use of serum transthyretin as a prognostic indicator and predictor of outcome in cardiac amyloid disease associated with wild-type transthyretin. Circ Heart Fail. 2018;11(2):e004000. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.117.004000.","journal-title":"Circ Heart Fail"},{"key":"696_CR36","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1146\/annurev.nu.14.070194.002431","volume":"14","author":"Y Ingenbleek","year":"1994","unstructured":"Ingenbleek Y, Young V. Transthyretin (prealbumin) in health and disease: nutritional implications. Annu Rev Nutr. 1994;14:495\u2013533. https:\/\/doi.org\/10.1146\/annurev.nu.14.070194.002431.","journal-title":"Annu Rev Nutr"},{"issue":"3","key":"696_CR37","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1515\/CCLM.2007.051","volume":"45","author":"A Myron Johnson","year":"2007","unstructured":"Myron Johnson A, Merlini G, Sheldon J, Ichihara K. Scientific division committee on plasma proteins IFoCC, laboratory M. clinical indications for plasma protein assays: transthyretin (prealbumin) in inflammation and malnutrition. Clin Chem Lab Med. 2007;45(3):419\u201326. https:\/\/doi.org\/10.1515\/CCLM.2007.051.","journal-title":"Clin Chem Lab Med"},{"issue":"3","key":"696_CR38","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/jamacardio.2020.5969","volume":"6","author":"AM Greve","year":"2021","unstructured":"Greve AM, Christoffersen M, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A. Association of low plasma transthyretin concentration with risk of heart failure in the general population. JAMA Cardiol. 2021;6(3):258\u201366. https:\/\/doi.org\/10.1001\/jamacardio.2020.5969.","journal-title":"JAMA Cardiol"},{"issue":"4","key":"696_CR39","first-page":"590","volume":"102","author":"MJ Saraiva","year":"1983","unstructured":"Saraiva MJ, Costa PP, Goodman DS. Studies on plasma transthyretin (prealbumin) in familial amyloidotic polyneuropathy Portuguese type. J Lab Clin Med. 1983;102(4):590\u2013603.","journal-title":"J Lab Clin Med"},{"issue":"4","key":"696_CR40","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1159\/000116264","volume":"28","author":"S Shoji","year":"1988","unstructured":"Shoji S, Nakagawa S. Serum prealbumin and retinol-binding protein concentrations in Japanese-type familial amyloid polyneuropathy. Eur Neurol. 1988;28(4):191\u20133. https:\/\/doi.org\/10.1159\/000116264.","journal-title":"Eur Neurol"},{"issue":"4","key":"696_CR41","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/13506120802525285","volume":"15","author":"J Buxbaum","year":"2008","unstructured":"Buxbaum J, Koziol J, Connors LH. Serum transthyretin levels in senile systemic amyloidosis: effects of age, gender and ethnicity. Amyloid. 2008;15(4):255\u201361. https:\/\/doi.org\/10.1080\/13506120802525285.","journal-title":"Amyloid"},{"issue":"6","key":"696_CR42","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1161\/ATVBAHA.113.301273","volume":"33","author":"LS Hornstrup","year":"2013","unstructured":"Hornstrup LS, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A. Genetic stabilization of transthyretin, cerebrovascular disease, and life expectancy. Arterioscler Thromb Vasc Biol. 2013;33(6):1441\u20137. https:\/\/doi.org\/10.1161\/ATVBAHA.113.301273.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"14","key":"696_CR43","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1093\/eurheartj\/ehz905","volume":"41","author":"L Chacko","year":"2020","unstructured":"Chacko L, Martone R, Bandera F, Lane T, Martinez-Naharro A, Boldrini M, et al. Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. Eur Heart J. 2020;41(14):1439\u201347. https:\/\/doi.org\/10.1093\/eurheartj\/ehz905.","journal-title":"Eur Heart J"},{"issue":"5","key":"696_CR44","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/s11897-022-00570-1","volume":"19","author":"CJ Hood","year":"2022","unstructured":"Hood CJ, Hendren NS, Pedretti R, Roth LR, Saelices L, Grodin JL. Update on disease-specific biomarkers in transthyretin cardiac amyloidosis. Curr Heart Fail Rep. 2022;19(5):356\u201363. https:\/\/doi.org\/10.1007\/s11897-022-00570-1.","journal-title":"Curr Heart Fail Rep"},{"issue":"12","key":"696_CR45","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1021\/cb100144v","volume":"5","author":"SJ Hyung","year":"2010","unstructured":"Hyung SJ, Deroo S, Robinson CV. Retinol and retinol-binding protein stabilize transthyretin via formation of retinol transport complex. ACS Chem Biol. 2010;5(12):1137\u201346. https:\/\/doi.org\/10.1021\/cb100144v.","journal-title":"ACS Chem Biol"},{"issue":"38","key":"696_CR46","doi-asserted-by":"publisher","first-page":"23395","DOI":"10.1016\/S0021-9258(17)31527-2","volume":"269","author":"R Berni","year":"1994","unstructured":"Berni R, Malpeli G, Folli C, Murrell JR, Liepnieks JJ, Benson MD. The Ile-84\u2013>Ser amino acid substitution in transthyretin interferes with the interaction with plasma retinol-binding protein. J Biol Chem. 1994;269(38):23395\u20138.","journal-title":"J Biol Chem"},{"issue":"3","key":"696_CR47","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1001\/jamacardio.2016.5864","volume":"2","author":"M Arvanitis","year":"2017","unstructured":"Arvanitis M, Koch CM, Chan GG, Torres-Arancivia C, LaValley MP, Jacobson DR, et al. Identification of transthyretin cardiac amyloidosis using serum retinol-binding protein 4 and a clinical prediction model. JAMA Cardiol. 2017;2(3):305\u201313. https:\/\/doi.org\/10.1001\/jamacardio.2016.5864.","journal-title":"JAMA Cardiol"},{"issue":"9","key":"696_CR48","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.cardfail.2021.05.009","volume":"27","author":"AR Kontorovich","year":"2021","unstructured":"Kontorovich AR, Abul-Husn NS. Retinol binding protein 4 as a screening biomarker for hereditary TTR amyloidosis in African American adults with TTR V142I. J Card Fail. 2021;27(9):1020\u20132. https:\/\/doi.org\/10.1016\/j.cardfail.2021.05.009.","journal-title":"J Card Fail"},{"key":"696_CR49","doi-asserted-by":"publisher","unstructured":"Schonhoft JD, Monteiro C, Plate L, Eisele YS, Kelly JM, Boland D, et al. Peptide probes detect misfolded transthyretin oligomers in plasma of hereditary amyloidosis patients. Sci Transl Med. 2017;9(407):eaam7621. https:\/\/doi.org\/10.1126\/scitranslmed.aam7621.","DOI":"10.1126\/scitranslmed.aam7621"},{"key":"696_CR50","doi-asserted-by":"publisher","unstructured":"Jiang X, Labaudiniere R, Buxbaum JN, Monteiro C, Novais M, Coelho T, et al. A circulating, disease-specific, mechanism-linked biomarker for ATTR polyneuropathy diagnosis and response to therapy prediction. Proc Natl Acad Sci U S A. 2021;118(9):e2016072118. https:\/\/doi.org\/10.1073\/pnas.2016072118.","DOI":"10.1073\/pnas.2016072118"},{"key":"696_CR51","doi-asserted-by":"publisher","unstructured":"Pires RH, Saraiva MJ, Damas AM, Kellermayer MS. Force spectroscopy reveals the presence of structurally modified dimers in transthyretin amyloid annular oligomers. J Mol Recognit. 2017;30(3):e2587. https:\/\/doi.org\/10.1002\/jmr.2587.","DOI":"10.1002\/jmr.2587"},{"key":"696_CR52","doi-asserted-by":"publisher","first-page":"102280","DOI":"10.1016\/j.cbpa.2023.102280","volume":"73","author":"X Sun","year":"2023","unstructured":"Sun X, Dyson HJ, Wright PE. Role of conformational dynamics in pathogenic protein aggregation. Curr Opin Chem Biol. 2023;73:102280. https:\/\/doi.org\/10.1016\/j.cbpa.2023.102280.","journal-title":"Curr Opin Chem Biol"},{"issue":"4","key":"696_CR53","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1080\/13506129.2024.2404073","volume":"31","author":"R Pedretti","year":"2024","unstructured":"Pedretti R, Wang L, Grodin JL, Masri A, Kelly J, Saelices L. Detection of ATTR aggregates in the plasma of polyneuropathic patients with ATTR-V30M amyloidosis. Amyloid. 2024;31(4):350\u20132. https:\/\/doi.org\/10.1080\/13506129.2024.2404073.","journal-title":"Amyloid"},{"issue":"21","key":"696_CR54","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1161\/CIRCULATIONAHA.123.067225","volume":"149","author":"R Pedretti","year":"2024","unstructured":"Pedretti R, Wang L, Hanna M, Benson MD, Grodin JL, Tang WHW, et al. Detection of circulating transthyretin amyloid aggregates in plasma: A novel biomarker for transthyretin amyloidosis. Circulation. 2024;149(21):1696\u20139. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.067225.","journal-title":"Circulation"},{"issue":"9","key":"696_CR55","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.jacbts.2024.05.013","volume":"9","author":"R Pedretti","year":"2024","unstructured":"Pedretti R, Wang L, Yakubovska A, Zhang QS, Nguyen B, Grodin JL, et al. Structure-based probe reveals the presence of large transthyretin aggregates in plasma of ATTR amyloidosis patients. JACC Basic Transl Sci. 2024;9(9):1088\u2013100. https:\/\/doi.org\/10.1016\/j.jacbts.2024.05.013.","journal-title":"JACC Basic Transl Sci"},{"issue":"29","key":"696_CR56","doi-asserted-by":"publisher","first-page":"E6741","DOI":"10.1073\/pnas.1805131115","volume":"115","author":"L Saelices","year":"2018","unstructured":"Saelices L, Chung K, Lee JH, Cohn W, Whitelegge JP, Benson MD, et al. Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition. Proc Natl Acad Sci U S A. 2018;115(29):E6741\u201350. https:\/\/doi.org\/10.1073\/pnas.1805131115.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"696_CR57","doi-asserted-by":"publisher","first-page":"6130","DOI":"10.1074\/jbc.RA118.005257","volume":"294","author":"L Saelices","year":"2019","unstructured":"Saelices L, Nguyen BA, Chung K, Wang Y, Ortega A, Lee JH, et al. A pair of peptides inhibits seeding of the hormone transporter transthyretin into amyloid fibrils. J Biol Chem. 2019;294(15):6130\u201341. https:\/\/doi.org\/10.1074\/jbc.RA118.005257.","journal-title":"J Biol Chem"},{"issue":"1","key":"696_CR58","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41467-024-44820-3","volume":"15","author":"BA Nguyen","year":"2024","unstructured":"Nguyen BA, Singh V, Afrin S, Yakubovska A, Wang L, Ahmed Y, et al. Structural polymorphism of amyloid fibrils in ATTR amyloidosis revealed by cryo-electron microscopy. Nat Commun. 2024;15(1):581. https:\/\/doi.org\/10.1038\/s41467-024-44820-3.","journal-title":"Nat Commun"},{"issue":"17","key":"696_CR59","doi-asserted-by":"publisher","first-page":"10467","DOI":"10.1016\/S0021-9258(18)34041-9","volume":"257","author":"JP Julien","year":"1982","unstructured":"Julien JP, Mushynski WE. Multiple phosphorylation sites in mammalian neurofilament polypeptides. J Biol Chem. 1982;257(17):10467\u201370.","journal-title":"J Biol Chem"},{"issue":"2","key":"696_CR60","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/0896-6273(94)90280-1","volume":"12","author":"J Eyer","year":"1994","unstructured":"Eyer J, Peterson A. Neurofilament-deficient axons and perikaryal aggregates in viable transgenic mice expressing a neurofilament-beta-galactosidase fusion protein. Neuron. 1994;12(2):389\u2013405. https:\/\/doi.org\/10.1016\/0896-6273(94)90280-1.","journal-title":"Neuron"},{"issue":"10","key":"696_CR61","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1073\/pnas.84.10.3472","volume":"84","author":"PN Hoffman","year":"1987","unstructured":"Hoffman PN, Cleveland DW, Griffin JW, Landes PW, Cowan NJ, Price DL. Neurofilament gene expression: a major determinant of axonal caliber. Proc Natl Acad Sci U S A. 1987;84(10):3472\u20136. https:\/\/doi.org\/10.1073\/pnas.84.10.3472.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"696_CR62","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1046\/j.1471-4159.1996.67052013.x","volume":"67","author":"LE Rosengren","year":"1996","unstructured":"Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelso C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem. 1996;67(5):2013\u20138. https:\/\/doi.org\/10.1046\/j.1471-4159.1996.67052013.x.","journal-title":"J Neurochem"},{"issue":"5","key":"696_CR63","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1212\/wnl.52.5.1090","volume":"52","author":"LE Rosengren","year":"1999","unstructured":"Rosengren LE, Karlsson JE, Sjogren M, Blennow K, Wallin A. Neurofilament protein levels in CSF are increased in dementia. Neurology. 1999;52(5):1090\u20133. https:\/\/doi.org\/10.1212\/wnl.52.5.1090.","journal-title":"Neurology"},{"issue":"21","key":"696_CR64","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1212\/WNL.0000000000001015","volume":"83","author":"T Skillback","year":"2014","unstructured":"Skillback T, Farahmand B, Bartlett JW, Rosen C, Mattsson N, Nagga K, et al. CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. Neurology. 2014;83(21):1945\u201353. https:\/\/doi.org\/10.1212\/WNL.0000000000001015.","journal-title":"Neurology"},{"issue":"1","key":"696_CR65","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/s41467-020-14612-6","volume":"11","author":"M Khalil","year":"2020","unstructured":"Khalil M, Pirpamer L, Hofer E, Voortman MM, Barro C, Leppert D, et al. Serum neurofilament light levels in normal aging and their association with morphologic brain changes. Nat Commun. 2020;11(1):812. https:\/\/doi.org\/10.1038\/s41467-020-14612-6.","journal-title":"Nat Commun"},{"issue":"3","key":"696_CR66","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1001\/jamaneurol.2018.3746","volume":"76","author":"B Olsson","year":"2019","unstructured":"Olsson B, Portelius E, Cullen NC, Sandelius A, Zetterberg H, Andreasson U, et al. Association of cerebrospinal fluid neurofilament light protein levels with cognition in patients with dementia, motor neuron disease, and movement disorders. JAMA Neurol. 2019;76(3):318\u201325. https:\/\/doi.org\/10.1001\/jamaneurol.2018.3746.","journal-title":"JAMA Neurol"},{"issue":"4","key":"696_CR67","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/jns.12350","volume":"24","author":"M Kapoor","year":"2019","unstructured":"Kapoor M, Foiani M, Heslegrave A, Zetterberg H, Lunn MP, Malaspina A, et al. Plasma neurofilament light chain concentration is increased and correlates with the severity of neuropathy in hereditary transthyretin amyloidosis. J Peripher Nerv Syst. 2019;24(4):314\u20139. https:\/\/doi.org\/10.1111\/jns.12350.","journal-title":"J Peripher Nerv Syst"},{"issue":"3","key":"696_CR68","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/jns.12084","volume":"19","author":"R Sadjadi","year":"2014","unstructured":"Sadjadi R, Reilly MM, Shy ME, Pareyson D, Laura M, Murphy S, et al. Psychometrics evaluation of charcot-marie-tooth neuropathy score (CMTNSv2) second version, using rasch analysis. J Peripher Nerv Syst. 2014;19(3):192\u20136. https:\/\/doi.org\/10.1111\/jns.12084.","journal-title":"J Peripher Nerv Syst"},{"issue":"8","key":"696_CR69","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1212\/WNL.0000000000001870","volume":"85","author":"D Adams","year":"2015","unstructured":"Adams D, Coelho T, Obici L, Merlini G, Mincheva Z, Suanprasert N, et al. Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study. Neurology. 2015;85(8):675\u201382. https:\/\/doi.org\/10.1212\/WNL.0000000000001870.","journal-title":"Neurology"},{"issue":"2","key":"696_CR70","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1080\/13506129.2019.1708716","volume":"27","author":"LF Maia","year":"2020","unstructured":"Maia LF, Maceski A, Conceicao I, Obici L, Magalhaes R, Cortese A, et al. Plasma neurofilament light chain: an early biomarker for hereditary ATTR amyloid polyneuropathy. Amyloid. 2020;27(2):97\u2013102. https:\/\/doi.org\/10.1080\/13506129.2019.1708716.","journal-title":"Amyloid"},{"issue":"4","key":"696_CR71","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1007\/s10072-021-05850-7","volume":"43","author":"M Luigetti","year":"2022","unstructured":"Luigetti M, Di Paolantonio A, Guglielmino V, Romano A, Rossi S, Sabino A, et al. Neurofilament light chain as a disease severity biomarker in ATTRv: data from a single-centre experience. Neurol Sci. 2022;43(4):2845\u20138. https:\/\/doi.org\/10.1007\/s10072-021-05850-7.","journal-title":"Neurol Sci"}],"container-title":["Current Heart Failure Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-025-00696-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11897-025-00696-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-025-00696-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T06:24:46Z","timestamp":1768544686000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11897-025-00696-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["696"],"URL":"https:\/\/doi.org\/10.1007\/s11897-025-00696-y","relation":{},"ISSN":["1546-9530","1546-9549"],"issn-type":[{"value":"1546-9530","type":"print"},{"value":"1546-9549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,13]]},"assertion":[{"value":"30 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}],"article-number":"8"}}